

URGENT FIELD SAFETY NOTICE

Commercial name of the affected product: cMYC (MYC) Breakapart

FSCA identifier: MDR009

Type of action: Advice

Date: 20th April 2018

Product name(s): cMYC (MYC) Breakapart

Catalogue number (s): LPH010, LPH010-20, LPH010-S

Lot number(s): All lots

Product expiry date(s): N/A

Dear Customer/Distributor,

Technical details:

As a result of a customer complaint we are notifying customers to advise that they fully review the Instructions For Use supplied with the product, in particular the chromosome map and probe specifications, to ensure all users are aware of the probe design.

cMYC (MYC) Breakapart is a dual colour MYC breakapart FISH probe which is constructed with a red clone proximal to the MYC region and a green clone distal to MYC region. The red and green clones in cMYC (MYC) Breakapart span the region bounded by the POU5F1B and PVT1 genes.

Cytocell have assessed there is a residual risk with this probe that a user may test a sample for the presence of a MYC rearrangement and issue a false negative result, if a breakpoint falls outside the region covered by the probe. A false negative result within a patient testing pathway may contribute to a patient being mis-classified as MYC rearrangement-negative and/or under-treated.

Cytocell have assessed this risk by undertaking a review of the potential MYC breakpoints by investigating the common diseases showing MYC rearrangements that may be investigated using FISH: diffuse large B-cell lymphoma (DLBCL), Burkitt Lymphoma and multiple myeloma. The majority of MYC rearrangements, including those seen in Burkitt lymphoma, do lie within the breakapart region of the LPH010 probe with the following notable exceptions:

1. Disease: DLBCL. MYC rearrangements with non-IG partners may have breakpoints outside the probe region. In one study, the MYC breakpoints in 2 out of 17 MYC rearrangements with non-IG partners (unspecified partners) lie distal to the LPH010 probe set¹. The LPH010 cMYC (MYC) Breakapart probe is designed for haematology applications; it is anticipated that DLBCL samples for MYC analysis would be received as FFPE samples, where the LPS027 MYC Breakapart probe set would be used, which includes this breakpoint region.

Cytocell Ltd
3-4 Technopark
Newmarket Road
Cambridge
CB5 8PB

T: +44 (0)1223 294048

F: +44 (0)1223 294986

www.cytocell.com

2. Disease: Multiple Myeloma. Some MYC rearrangements in multiple myeloma may have breakpoints outside the probe region. Secondary MYC rearrangements in multiple myeloma are reported in approximately 21% of cases of multiple myeloma and the MYC breakpoints in a subset of these rearrangements may lie distal to the region bounded by the LPH010 probe set². These cases would be picked up by the LPS027 probe set.

Thus the probability of occurrence of a false negative result is dependent on the disease state, a summary of which is provided below:

1. Within Burkitt Lymphoma – Negligible.
2. Within DLBCL – low (unlikely to happen).
3. Within multiple myeloma – very low (very unlikely to happen).

The device can continue to be used, provided it is still within its stated expiry date. Cytocell intend to update the Instructions For Use supplied with the product to highlight its design to users more effectively.

References:

1. Bertrand P, Bastard C, Maingonnat C, Jardin F, Maisonneuve C, Courel M-N, et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. *Leukemia*;2007 Mar;21(3):515–23.
2. Walker BA, Wardell CP, Brioli A, Boyle E, Kaiser MF, Begum DB, et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. *Blood Cancer J [Internet]*. Nature Publishing Group; 2014 Mar 14;4(3):e191.

Recommended actions for users:

Our records indicate you have received the aforementioned device.

Cytocell recommends that users continue to use the device, but requests that they review the Instructions for Use to ensure that the probe design is suitable for their clinical application in line with the limitations outlined in this Field Safety Notice. All devices still within their stated expiry date can continue to be used as the device has not malfunctioned.


With this Field Safety Notice we have supplied a Declaration Form MDR009. Please return this completed document within 2 weeks.

Transmission of this Field Safety Notice:

This notice needs to be passed on to all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred.

We wish to sincerely apologise for any inconvenience caused as a result of this Urgent Field Safety Notice. If you have any questions or comments arising from this Urgent Field Safety Notice, please contact us at on +44(0) 1223 294048 or email us at regaffairs@ogt.com.

Yours sincerely,



Paul Kenny
Executive Vice President of Regulatory Affairs
Cytocell Ltd.

Cytocell Ltd
3-4 Technopark
Newmarket Road
Cambridge
CB5 8PB

T: +44 (0)1223 294048

F: +44 (0)1223 294986

www.cytocell.com

DECLARATION FORM

Commercial name of the affected product: cMYC (MYC) Breakapart

FSCA identifier: MDR009

Type of action: Advice

Email: regaffairs@ogt.com or **Fax to:** +44 (0) 1223 294986

Customer Information

Organisation:

Address:

Contact person:

Declaration

I hereby confirm that we have read and understood the Urgent Field Safety Notice on LPH010, LPH010-20, LPH010-S cMYC (MYC) Breakapart probe and we have communicated this to all our end users of the above stated device.

As declared by (name):

Job Title:

Signature and date:

Please sign this form and return the completed document (by FAX or as a scanned PDF) to the address provided above within two weeks.